Chief, Division of Head and Neck Medical Oncology
Associate Professor, Department of Hematology/Oncology
Director, Hematology/Oncology Fellowship Training Program
NCCN, Non-Small Cell Lung Cancer/Malignant Pleural Mesothelimoa/Thymomas and Thymic Carcinomas Panel Member
Head & Neck Cancer, Mesothelioma, Endobronchial Disease, Lung Metastases, Thyroid Cancer, Lung Cancer, Thymoma
Head and Neck and Thoracic Oncology
I was excited to return to Philadelphia to join the Fox Chase Cancer Center in 2015 after completing my fellowship in medical oncology at Dana Farber Cancer Institute/Massachusetts General Hospital in Boston, MA. From the moment I walked in to Fox Chase for the first time, every person I met was incredibly caring and dedicated to providing thoughtful, comprehensive, compassionate care for every patient and family. I knew I would fit right in.
I wanted to be an oncologist starting in medical school. I was struck by the profound responsibility we have as physicians to patients and their families facing illness of any kind: our responsibility to explain illness, to obtain the knowledge to provide the best, most up-to-date treatments available, to know our patients, to ask the right questions, and above all, to listen. I was particularly inspired and humbled by my patients with cancer and their families as I accompanied them on their cancer journey, and knew immediately that I wanted to dedicate my career to being an oncologist.
Within oncology, I specialize in lung cancer and head and neck cancer. In both of these fields, there are exciting advances in our understanding of how these cancers form and how they respond to new, innovative treatments. My research interest is in optimizing supportive care, communication, and quality of life for patients and their families facing cancer, while simultaneously providing state of the art cancer treatments. Additionally, I am interested in developing educational tools that help patients and families better understand cancer and treatments as well as help with symptom management, mood, and satisfaction with care.
In 2011, when my first son was not quite a year old, I had a small dysplasia, which is a precancerous lesion, on my tongue. A surgical oncologist at Fox Chase Cancer Center, did the surgery to remove it. Everything went really well.
A few days before leaving on my vacation in August, 2017, I noticed a loose tooth. My biggest worry was that maybe I had an abscess and it would ruin my trip.
When I got home, my dentist said I should have it pulled, so I went to an oral surgeon. The oral surgeon said, “I see something, so I’m going to do a biopsy.” I kind of knew right then that I had cancer.
I tell people if you are going on this journey, you should not compare yourself to anyone else. Every cancer is different, and every person’s situation is different.
Before cancer, I was a retired Philadelphia police officer who enjoyed many wonderful adventures with my husband, Braco. We enjoyed running businesses together, traveling together, and raising our daughters together. But, when Braco was diagnosed with lung cancer in 2016 at the age of 57, everything changed. And, a few years later in 2019, I was faced with my own lung cancer diagnosis.
Interested in optimizing communication, quality of life, and palliative and supportive care for patients and their families facing cancer. Additionally, she is interested in developing new therapeutic approaches for treating advanced head and neck and thoracic malignancies.
Head and neck cancer:
Giri A, Bauman JR. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. Expert Review of Anticancer Therapy. 2022 Sep.
Weiss J, Sheth S, Deal AM, Grilley Olson JE, Patel S, Hackman TG, Blumberg JM, Galloway T, Patel S, Zanation AM, Shen CJ, Hayes DN, Hilliard C, Mehra R, McKinnon KP, Wang HH, Weissler MC, Bauman JR, Chera BS, Vincent BG. Concurrent definitive immunoradiotherapy for patients with Stage III-IV Head and Neck Cancer and Cisplatin contraindication. Clin Cancer Res. 2020 May 5.
Grob JJ, Gonzalez R, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats JM, Bauman JR, Zhang P, Gumuscu B, Swaby R, Hughes B. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol. 2020 Sep 1;38(25):2916-2925.
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 Mar 22.
Mercadante V, Jensen SB, Smith DK, Bohlke K, Bauman J, Brennan MT, Coppes RP, Jessen N, Malhotra NK, Murphy B, Rosenthal DI, Vissink A, Wu J, Saunders DP, Peterson DE. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. J Clin Oncol. 2021 Sep 1;39(25):2825-2843.
Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022 Apr 29;186(6):631-643. PMID: 35333737.
Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, Patil T, McDermott R, Raez LE, Johnson JM, Shen L, Tahara M, Ho AL, Norenberg R, Dima L, Brega N, Drilon A, Hong DS. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist. 2022 May 10.
Zarrabi KK, Galloway TG, Flieder DB, Kumar SS, Judd J, Bauman JR. Assessing plasma circulating tumor human papillomavirus (HPV) DNA in determining treatment response in HPV-associated oropharyngeal cancer. Head Neck. 12 May 2022.
Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. J Clin Oncol. 2023 Mar 28:JCO2201994.
Lung cancer:
Bauman JR, Edelman MJ. Targeted Therapies in Non-Small Cell Lung Cancer. Advanced in Radiation Oncology in Lung Cancer, 3rd Ed. May 2023.
Bauman J, Borghaei H. To give or not to give: consolidative durvalumab in EGFR-mutant NSCLC. Journal of Thoracic Oncology. 2021 June; 16(6):894-896.
Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F,
Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021 Feb 24.
Bodor JN, Bauman JR, Handorf EA, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Cancer Res Clin Oncol. 2022 Jun 16.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023 Apr;21(4):340-350.
Supportive care:
Bauman, Jessica, Temel, Jennifer. The integration of early palliative care with oncology care: the time has come for a new tradition. J Natl Compr Canc Netw. 2014 Dec;12(12):1763-71.
Senchak JJ, Fang CY, Bauman JR. Cancers Head Neck. 2019 Jun 11;4:2.
Albert MJ, Collins ME, Bauman JR. Hematology/Oncology Fellows' Training in Palliative Care: A Narrative Review. J Palliat Med. 2023 Jul;26(7):999-1008.
Bauman J, El-jawahri A. One size does not fit all: The need for population-specific palliative care interventions, Re: Patil, et al: Effect of early palliative care on the QOL of patients with advanced head and neck cancers: A phase 3 trial. JNCI. 2021 Feb 16.
Bauman, J, Schleicher, S, Nipp, R, El-Jawahri, A, Pirl, W, Greer, J, Temel J. A pilot study to Enhance Communication with Oncology during Hospice care. Journal for Community and Supportive Oncology. April 29, 2018.
Fang CY, Galloway TJ, Egleston BL, Bauman JR, Ebersole B, Chwistek M, Bühler JG, Longacre ML, Ridge JA, Manne SL, Manning C (2020). Development of a Web-Based Supportive Care Program for Patients With Head and Neck Cancer. Front. Oncol. Dec 2020.
Ebersole B, McCarroll L, Ridge JA, Liu JC, Bauman J, Donnelly S, Galloway TJ. Identification and Management of Late Dysfunction in Survivors of Head and Neck Cancer: Implementation and Outcomes of an Interdisciplinary Quality of Life (IQOL) Clinic. Head Neck. 2021; 43:2124-2135.
Bauman J, Panick J, Galloway T, Ridge J, Chwistek M, Collins M, Kinczewski L, Murphy K, Welsh M, Farren M, Omilak M, Kelly J, Schuster K, Lucas L, Amrhein S, Bender F, Temel J, Egleston B, El-jawahri A, Fang C. A pilot study of a collaborative palliative and oncology care intervention for patients with head and neck cancer. Journal of Palliative Medicine; 2021 Apr 13.
Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin A. Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. J Natl Cancer Inst. 2021 Jul 22.
Patient comments